Melanoma Therapeutics: Which Strategy Will Take Us There? - Market Research Reports

Welcome - Home - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying

| More

Electronic (PDF)
Site License
Enterprisewide

Melanoma Therapeutics: Which Strategy Will Take Us There?
Bioseeker, July 2005, Pages: 204



		Description


	Table of Contents



		Companies Mentioned



		Enquire before Buying



		Send to a Friend

List of Figures

List of Tables

List of Boxes

Methodology

Etiology and Pathophysiology

Key Therapy Strategies

Immunotherapy

Cancer Vaccines

Antiangiogenesis

Gene Therapy

Current Treatment Regimens

An Overview

Cytotoxic Drugs

Dacarbazine

Cisplatin

Carboplatin

Carmustine

Melphalan

Paclitaxel

Tamoxifen

Temozolomide

Vinblastine/Vinorelbine

Biological treatments

Virulizin

Melacine

Alfanative (Multiferon)

Proleukin or (Macrolin)

Ceplene Maxamine

Competitive Lanscape in Melanoma R&D

Phase I & II R&D Collaborations in Melanoma: Oxxon

Roche links Schering-Plough and Chugai Clusters Together - What Will the Outcome Be?

GlaxoSmithKline Brings Wyeth, Hayashibara, Cytokinetics and Coley Pharmaceuticals Together

GlaxoSmithKline and Sanofi-Aventis have a Joint Middle Man

R&D Collaboration Trends in Melanoma Projects

Current Melanoma Drug Development

Vaccines: Active Immunotherapy a Benefit or Not?

Vaccine: Direct Immunization with Tumor Antigens

Vaccines: Is the Development of Cell Therapy Stalling?

DNA Vaccine

Vaccine Adjuvants

Immunostimulants: The Push in Passive Immunotherapy

Immuno-Biologicals: The Work Horse

Immunostimulation by Gene Therapy

One Small Molecular Drug Candidate

Antiongiogenesis- The Major Research Focus for the Next Decade?

Apoptosis Inducers: Moving into Market

Small Molecules Inhibiting Cell Growth Faces Difficulties

Other Biological Drugs

Disclaimer

Selected Company Profiles

Index

Appendix I: Treatment Guide Lines Melanoma

Customers who bought this item also bought

Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma

Gene Therapy - Technologies, Markets and Companies

Disease and Therapy Review: Melanoma

Stakeholder Opinions: Malignant Melanoma - High Hurdles, High Rewards, Are Vaccines Only Skin Deep?

Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma

Strategic Perspectives: Malignant Melanoma - Biotechnology-Driven Agents Finding a Flagship Indication?

Stakeholder Opinions: Melanoma - Lucrative Commercial Opportunities Persist

Currently Druggable in Melanoma: A Drug Target Competitive Analysis

Cell Therapy - Technologies, Markets and Companies

Cancer Cell Therapy Markets

Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC

Gene Therapy - Global Strategic Business Report

Top of page